- ZEVASKYN is the only FDA-approved therapy to treat RDEB wounds with a single application - ...

Historic achievement: FDA approval of Abeona Therapeutics' ZEVASKYN accelerates momentum and expands treatment options for the EB community. Provided by PR Newswire Apr 29, 2025, 4:32:00 PM.

FDA approval for ZEVASKYN underscores its significance as a groundbreaking treatment in the field of gene therapy, enhancing Abeona’s position in the biopharmaceutical market.

CLEVELAND, April 29, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the U.S. Food and Drug Administration (FDA) has approved ZEVASKYN™ (pronounced as ‘ZEE-vah ...

ZEVASKYN is the first FDA-approved autologous cell-based gene therapy for treating wounds associated with RDEB, a severe skin disease that causes large, painful wounds and a high risk of cancer.

Abeona Therapeutics enters Q2 2025 as a commercial-stage company with ZEVASKYN FDA approval, first patient site activation, and a $155 million PRV sale supporting a cash runway toward projected ...

EB Research Partnership ("EBRP") invested in the work that led to ZEVASKYN at Stanford University under their pioneering Venture Philanthropy Model. This approval marks a historic moment for the EB ...

CLEVELAND, April 29, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the U.S. Food and Drug Administration (FDA) has approved ZEVASKYN™ (pronounced as ‘ZEE-vah-skin’) ...